(NASDAQ: NEO) Neogenomics's forecast annual revenue growth rate of 8.3% is forecast to beat the US Diagnostics & Research industry's average forecast revenue growth rate of 8.2%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.69%.
Neogenomics's revenue in 2026 is $766,295,000.On average, 13 Wall Street analysts forecast NEO's revenue for 2026 to be $103,864,684,714, with the lowest NEO revenue forecast at $100,573,143,941, and the highest NEO revenue forecast at $108,284,239,850. On average, 13 Wall Street analysts forecast NEO's revenue for 2027 to be $114,276,334,371, with the lowest NEO revenue forecast at $110,016,088,781, and the highest NEO revenue forecast at $119,385,802,620.
In 2028, NEO is forecast to generate $125,169,766,929 in revenue, with the lowest revenue forecast at $120,416,175,649 and the highest revenue forecast at $130,916,473,360.